Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA

Lab / animal OA: closed
📄 Open PDF View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-09-05 ⓘ

Ribozymes targeting Flt-1 and KDR mRNA reduced VEGF-induced endothelial cell proliferation and exhibited anti-angiogenic activity in a rat corneal pocket assay, demonstrating their potential for studying VEGF receptor function.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Vascular endothelial growth factor (VEGF) and its receptors Flt-1 and KDR play important roles in physiological and pathological angiogenesis. Ribozymes that target the VEGF receptor mRNAs were developed and their biological activities in cell culture and an animal model were assessed. Ribozymes targeting Flt-1 or KDR mRNA sites reduced VEGF-induced proliferation of cultured human vascular endothelial cells and specifically lowered the level of Flt-1 or KDR mRNA present in the cells. Anti- Flt-1 and KDR ribozymes also exhibited anti-angiogenic activity in a rat corneal pocket assay of VEGF-induced angiogenesis. This report illustrates the anti-angiogenic potential of these ribozymes as well as their value in studying VEGF receptor function in normal and pathophysiologic states.

My notes (saved in your browser only)

MeSH descriptors

Endothelium, Vascular Proto-Oncogene Proteins Receptor Protein-Tyrosine Kinases Receptors, Growth Factor RNA, Catalytic Animals Endothelium, Vascular Endothelium, Vascular Gene Expression Regulation Gene Expression Regulation Gene Targeting Humans Male Neovascularization, Pathologic Neovascularization, Pathologic Neovascularization, Pathologic Neovascularization, Physiologic Neovascularization, Physiologic Proto-Oncogene Proteins Rats

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-10-11T09:27:45.537177+00:00
pubmed
last seen: 2026-10-08T20:58:57.924351+00:00
unpaywall
last seen: 2026-10-13T06:25:51.201866+00:00